{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:56:36Z","timestamp":1794617796770,"version":"4.9.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>Uterine Fibroids, or leiomyomata, affect millions of women world-wide, with a high incidence of 75% within women of reproductive age. In ~30% of patients, uterine fibroids cause menorrhagia, or heavy menstrual bleeding, and more than half of the patients experience symptoms such as heavy menstrual bleeding, pelvic pain, or infertility. Treatment is symptomatic with limited options including hysterectomy as the most radical solution. The genetic foundations of uterine fibroid growth have been traced to somatic driver mutations (<jats:italic>MED12, HMGA2, FH<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup>, and <jats:italic>COL4A5-A6<\/jats:italic>). These also lead to downstream expression of angiogenic factors including IGF-1 and IGF-2, as opposed to the VEGF-driven mechanism found in the angiogenesis of hypoxic tumors. The resulting vasculature supplying the fibroid with nutrients and oxygen is highly irregular. Of particular interest is the formation of a pseudocapsule around intramural fibroids, a unique structure within tumor angiogenesis. These aberrations in vascular architecture and network could explain the heavy menstrual bleeding observed. However, other theories have been proposed such as venous trunks, or venous lakes caused by the blocking of normal blood flow by uterine fibroids, or the increased local action of vasoactive growth factors. Here, we review and discuss the evidence for the various hypotheses proposed.<\/jats:p>","DOI":"10.3389\/frph.2022.818243","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:14:30Z","timestamp":1646370870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Uterine Fibroids (Leiomyomata) and Heavy Menstrual Bleeding"],"prefix":"10.3389","volume":"4","author":[{"given":"Outi","family":"Uimari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita S.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas T.","family":"Tapmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"B1","volume-title":"Heavy Menstrual Bleeding: Assessment and Management","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3109\/00016346609158455","article-title":"Menstrual blood loss\u2013a population study: variation at different ages and attempts to define normality","volume":"45","author":"Hallberg","year":"1966","journal-title":"Acta Obstet Gynecol Scand."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.ajog.2003.11.016","article-title":"Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?","volume":"190","author":"Warner","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/frph.2021.750018","article-title":"Endometriosis and uterine fibroids (leiomyomata): comorbidity, risks and implications","volume":"3","author":"Uimari","year":"2021","journal-title":"Front Reprod Heal."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e032220","DOI":"10.1136\/bmjopen-2019-032220","article-title":"Protocol for a longitudinal, prospective cohort study investigating the biology of uterine fibroids and endometriosis, and patients' quality of life: the FENOX study","volume":"10","author":"Tapmeier","year":"2020","journal-title":"BMJ Open."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","article-title":"Uterine fibroids","volume":"2","author":"Stewart","year":"2016","journal-title":"Nat Rev Dis Prim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/REP-16-0216","article-title":"Differences in the cellular composition of small vs. large uterine fibroids","volume":"152","author":"Holdsworth-Carson","year":"2016","journal-title":"Reproduction."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD003677","DOI":"10.1002\/14651858.CD003677.pub5","article-title":"Surgical approach to hysterectomy for benign gynaecological disease","volume":"2015","author":"Aarts","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"211.e1","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/humrep\/deh407","article-title":"Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study","volume":"19","author":"Marino","year":"2004","journal-title":"Hum Reprod."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Day Baird","year":"2003","journal-title":"Am J Obstet Gynecol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health."},{"key":"B13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00404-016-4239-y","article-title":"Symptoms of uterine myomas: data of an epidemiological study in Germany","volume":"295","author":"Foth","year":"2017","journal-title":"Arch Gynecol Obstet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.bpobgyn.2008.01.008","article-title":"Clinical presentation of fibroids","volume":"22","author":"Gupta","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Longo","year":"2013","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynecol Obstet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.fertnstert.2015.04.029","article-title":"Effect of menses on standardized assessment of sexual dysfunction among women with uterine fibroids: a cohort study","volume":"104","author":"Laughlin-Tommaso","year":"2015","journal-title":"Fertil Steril."},{"key":"B18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.22541\/au.161907774.45454712\/v1","article-title":"Appraisal of national and international uterine fibroid management guidelines: a systematic review","volume":"129","author":"Amoah","year":"2021","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.fertnstert.2017.11.033","article-title":"Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis","volume":"109","author":"Sandberg","year":"2018","journal-title":"Fertil Steril"},{"key":"B20","doi-asserted-by":"publisher","first-page":"CD000400","DOI":"10.1002\/14651858.CD000400.pub4","article-title":"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding","volume":"9","author":"Bofill Rodriguez","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1471-0528.1986.tb08019.x","article-title":"Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen","volume":"93","author":"M\u00e4k\u00e4r\u00e4inen","year":"1986","journal-title":"Br J Obstet Gynaecol."},{"key":"B22","first-page":"10","article-title":"Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia","volume":"68","author":"Ylikorkala","year":"1986","journal-title":"Obstet Gynecol."},{"key":"B23","volume-title":"Management of Uterine Fibroids. Comparative Effectiveness Review No. 195","author":"Hartmann","year":"2017"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S0015-0282(03)00175-4","article-title":"Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas","volume":"79","author":"Grigorieva","year":"2003","journal-title":"Fertil Steril."},{"key":"B25","doi-asserted-by":"publisher","first-page":"CD008994","DOI":"10.1002\/14651858.CD008994.pub2","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","volume":"2013","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD002126","DOI":"10.1002\/14651858.CD002126.pub4","article-title":"Progestogen-releasing intrauterine systems for heavy menstrual bleeding","volume":"2020","author":"Bofill Rodriguez","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.contraception.2010.02.011","article-title":"Intrauterine device use among women with uterine fibroids: a systematic review","volume":"82","author":"Zapata","year":"2010","journal-title":"Contraception."},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijgo.2011.07.031","article-title":"Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma","volume":"116","author":"Kriplani","year":"2012","journal-title":"Int J Gynecol Obstet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.12891\/ceog1826.2015","article-title":"Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma","volume":"42","author":"Senol","year":"2015","journal-title":"Clin Exp Obstet Gynecol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejogrb.2012.07.030","article-title":"Therapeutic management of uterine fibroid tumors: updated French guidelines","volume":"165","author":"Marret","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD010770","DOI":"10.1002\/14651858.CD010770.pub2","article-title":"Selective progesterone receptor modulators (SPRMs) for uterine fibroids","volume":"2017","author":"Murji","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","article-title":"Ulipristal acetate for treatment of uterine leiomyomas","volume":"132","author":"Liu","year":"2018","journal-title":"Obstet Gynecol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet Gynecol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/AOG.0000000000003211","article-title":"Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas","volume":"133","author":"Lukes","year":"2019","journal-title":"Obstet Gynecol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rbmo.2018.04.040","article-title":"Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review","volume":"37","author":"Donnez","year":"2018","journal-title":"Reprod Biomed Online."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/14740338.2018.1550070","article-title":"Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program","volume":"17","author":"Donnez","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"CD007687","DOI":"10.1002\/14651858.CD007687.pub2","article-title":"Mifepristone for uterine fibroids","volume":"2021","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med."},{"key":"B44","unstructured":"ChicagoOriahnnTM (Elagolix, Estradiol, Norethindrone Acetate Capsules Elagolix Capsules). Highlights of Prescribing Information2020"},{"key":"B45","unstructured":"2021"},{"key":"B46","unstructured":"Relugolix With Oestradiol and Norethisterone Acetate for Treating Uterine Fibroids [ID3842]2021"},{"key":"B47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/humrep\/det459","article-title":"Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms","volume":"29","author":"Torre","year":"2014","journal-title":"Hum Reprod."},{"key":"B48","doi-asserted-by":"publisher","first-page":"CD005073","DOI":"10.1002\/14651858.CD005073.pub4","article-title":"Uterine artery embolization for symptomatic uterine fibroids","volume":"2014","author":"Gupta","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1056\/NEJMoa062003","article-title":"Uterine-artery embolization versus surgery for symptomatic uterine fibroids","volume":"356","author":"Edwards","year":"2007","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","article-title":"Management of symptomatic uterine leiomyomas","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/1471-0528.14689","article-title":"Evaluation of high-intensity focused ultrasound ablation for uterine fibroids: an IDEAL prospective exploration study","volume":"125","author":"Chen","year":"2018","journal-title":"BJOG Int J Obstet Gynaecol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"519.e1","DOI":"10.1016\/j.ajog.2007.02.029","article-title":"Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial","volume":"196","author":"Volkers","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1007\/s00330-010-1829-0","article-title":"Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial","volume":"20","author":"Ruuskanen","year":"2010","journal-title":"Eur Radiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1148\/radiol.2463070260","article-title":"Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy\u2014results from the randomized clinical embolisation versus hysterectomy (EMMY) trial","volume":"246","author":"Hehenkamp","year":"2008","journal-title":"Radiology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"95.e1","DOI":"10.1016\/j.ajog.2018.05.004","article-title":"The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design","volume":"219","author":"Stewart","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/rep,.0.1210181","article-title":"Human endometrial angiogenesis","volume":"121","author":"Gargett","year":"2001","journal-title":"Reproduction."},{"key":"B57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bpobgyn.2008.01.005","article-title":"Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation","volume":"22","author":"Fleischer","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/humupd\/dmt042","article-title":"The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy","volume":"20","author":"Tal","year":"2014","journal-title":"Hum Reprod Update."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1073\/pnas.1518752113","article-title":"Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers","volume":"113","author":"Mehine","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"M\u00e4kinen","year":"2011","journal-title":"Science."},{"key":"B61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1302736","article-title":"Characterization of uterine leiomyomas by whole-genome sequencing","volume":"369","author":"Mehine","year":"2013","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.fertnstert.2020.07.044","article-title":"HMGA2 involvement in uterine leiomyomas development through angiogenesis activation","volume":"114","author":"Ferrero","year":"2020","journal-title":"Fertil Steril."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.fertnstert.2020.05.036","article-title":"HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma","volume":"114","author":"Li","year":"2020","journal-title":"Fertil Steril."},{"key":"B64","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrm2654","volume":"10","author":"Mosimann","year":"2009","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1095\/biolreprod.108.075648","article-title":"Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice","volume":"81","author":"Tanwar","year":"2009","journal-title":"Biol Reprod."},{"key":"B66","doi-asserted-by":"publisher","first-page":"en.2016","DOI":"10.1210\/en.2016-1097","article-title":"Silencing Med12 gene reduces proliferation of human leiomyoma cells mediated via Wnt\/\u03b2-catenin signaling pathway","volume":"158","author":"Al-Hendy","year":"2016","journal-title":"Endocrinology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JME-14-0215","article-title":"Endothelial cells and the IGF system","volume":"54","author":"Bach","year":"2014","journal-title":"J Mol Endocrinol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.bcp.2011.02.016","article-title":"The angiogenic process as a therapeutic target in cancer","volume":"81","author":"Bridges","year":"2011","journal-title":"Biochem Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1210\/jcem.80.6.7775632","article-title":"Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata","volume":"80","author":"Harrison-Woolrych","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1042\/CS20010096","article-title":"Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium","volume":"101","author":"Gentry","year":"2001","journal-title":"Clin Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/j.0001-6349.2005.00621.x","article-title":"Serum vascular endothelial growth factor 165 levels and uterine fibroid volume","volume":"84","author":"Chen","year":"2005","journal-title":"Acta Obstet Gynecol Scand."},{"key":"B73","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1933719112459233","article-title":"Fibroid-associated heavy menstrual bleeding: correlation between clinical features, doppler ultrasound assessment of vasculature, and tissue gene expression profiles","volume":"20","author":"Tsiligiannis","year":"2013","journal-title":"Reprod Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.fertnstert.2004.01.047","article-title":"Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis","volume":"82","author":"Hoffman","year":"2004","journal-title":"Fertil Steril."},{"key":"B75","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2119\/2007-00101.YU","article-title":"Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas","volume":"14","author":"Yu","year":"2008","journal-title":"Mol Med."},{"key":"B76","first-page":"2808","article-title":"Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density","volume":"6","author":"Hague","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia \u2014 a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/0008-5472.CAN-07-6339","article-title":"Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia","volume":"68","author":"Mayer","year":"2008","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-1-4419-1241-1_58","article-title":"HIF-mediated hypoxic response is missing in severely hypoxic uterine leiomyomas","volume-title":"Oxygen Transport to Tissue XXXI","author":"Mayer","year":"2010"},{"key":"B80","first-page":"226A","article-title":"Alternative angiogenesis mechanisms in uterine fibroids related to heavy menstrual bleeding","volume-title":"Reproductive Sciences","author":"Subramaniam","year":"2019"},{"key":"B81","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0015-0282(16)45789-4","article-title":"Uterine leiomyomata: etiology, symptomatology, and management","volume":"36","author":"Buttram","year":"1981","journal-title":"Fertil Steril."},{"key":"B82","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/molehr\/gat007","article-title":"Gene expression analysis reveals an angiogenic profile in uterine leiomyoma pseudocapsule","volume":"19","author":"Di Tommaso","year":"2013","journal-title":"Mol Hum Reprod."},{"key":"B83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.xfss.2020.11.001","article-title":"Summary of the proceedings of the Basic Science of Uterine Fibroids meeting: new developments (February 28, 2020)","volume":"2","author":"Leppert","year":"2021","journal-title":"F&S Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.24425\/fmc.2019.131378","article-title":"Telocytes in the architecture of uterine fibroids","volume":"59","author":"Aleksandrovych","year":"2019","journal-title":"Folia Med Cracov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1530\/REP-12-0369","article-title":"Telocytes: ultrastructural, immunohistochemical and electrophysiological characteristics in human myometrium","volume":"145","author":"Cretoiu","year":"2013","journal-title":"Reproduction."},{"key":"B86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mehy.2017.11.003","article-title":"Recently discovered interstitial cells \u201ctelocytes\u201d as players in the pathogenesis of uterine leiomyomas","volume":"110","author":"Varga","year":"2018","journal-title":"Med Hypotheses."},{"key":"B87","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000140175","article-title":"Arteriovenous anastomoses in the endometrium in man","volume":"1","author":"Schlegel","year":"1945","journal-title":"Cells Tissues Organs."},{"key":"B88","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1471-0528.1970.tb03439.x","article-title":"The vascular patterns in myomatous uteri","volume":"77","author":"Farrer-Brown","year":"1970","journal-title":"BJOG Int J Obstet Gynaecol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5603\/FM.2014.0024","article-title":"\u201cVenous lakes\u201d \u2014 a corrosion cast scanning electron microscopy study of regular and myomatous human uterine blood vessels","volume":"73","author":"Bereza","year":"2014","journal-title":"Folia Morphol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4236\/ojpathology.2014.44025","article-title":"Cyclic changes of lymphatic and venous vessels in human endometrium","volume":"4","author":"Tomita","year":"2014","journal-title":"Open J Pathol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/humupd\/2.4.295","article-title":"Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era","volume":"2","author":"Stewart","year":"1996","journal-title":"Hum Reprod Update."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1071 LP","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"B93","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet."},{"key":"B94","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"B95","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bpobgyn.2016.09.008","article-title":"The role of leiomyomas in the genesis of abnormal uterine bleeding (AUB)","volume":"40","author":"Lasmar","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1210\/jc.2004-0161","article-title":"Gonadotropin releasing hormone and transforming growth factor \u03b2 activate mitogen-activated protein kinase\/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomy","volume":"89","author":"Ding","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"B97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2174\/157340810791233033","article-title":"TGF-\u03b2: titan of lung fibrogenesis","volume":"6","author":"Yue","year":"2010","journal-title":"Curr Enzym Inhib."},{"key":"B99","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1210\/jc.2010-1450","article-title":"Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-\u03b23","volume":"96","author":"Sinclair","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/aji.12127","article-title":"Cytokine patterns differ seasonally between women with and without uterine leiomyomata","volume":"70","author":"Wegienka","year":"2013","journal-title":"Am J Reprod Immunol."}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2022.818243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:14:39Z","timestamp":1646370879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2022.818243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":100,"alternative-id":["10.3389\/frph.2022.818243"],"URL":"https:\/\/doi.org\/10.3389\/frph.2022.818243","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"article-number":"818243"}}